How it works
How Much Does CAR T-cell therapy Cost in China?
CAR T-cell therapy in China typically costs from $275,000 to $319,000. Prices depend on the specific cell product used, clinical protocol, and length of hospital stay. In the United States, similar procedures cost around $480,000 on average. Patients save around 38% compared to US costs. Standard Chinese packages usually include T-cell collection, laboratory manufacturing, lymphodepletion chemotherapy, and 30 days of specialized inpatient monitoring.
- Approved commercial therapies: $275,000 to $319,000 for NMPA-cleared products like Axi-cel or Relma-cel.
- Clinical trial pathways: Often range from 15% to 40% of the cost of commercial drugs.
- Administrative hubs: Specialized treatment centers are primarily located in Beijing, Shanghai, and Guangzhou.
- Inpatient monitoring: Typically covers a 4-week stay to manage cytokine release syndrome or neurotoxicity.
Bookimed Expert Insight: China represents a unique value for refractory blood cancers due to high treatment volumes. Beijing GoBroad Boren Hospital, a top hematology specialist, offers packages starting around $100,000. This includes a full 30-day hospital stay and comprehensive diagnostics. Facilities like Fuda Cancer Hospital hold JCI accreditation, ensuring international safety standards. For complex pediatric cases, centers like Beijing Kyoto Children's Hospital provide specialized wards for high-risk management.
| China | Turkey | Austria | |
|---|---|---|---|
| CAR T-cell therapy | from $275,000 | from $150,000 | ≈ $280,000 |
| CAR-T for Pediatric ALL | from $250,000 | ≈ $140,000 | ≈ $290,000 |
| CAR-T for Multiple Myeloma | from $250,000 | ≈ $140,000 | ≈ $330,000 |
| CAR-T for DLBCL | from $250,000 | ≈ $140,000 | ≈ $290,000 |
Discover the Best CAR T-cell therapy Clinics in China: 5 Verified Options and Prices
CAR T-cell therapy Overview in China
- CAR T-cell therapy - from $275,000This therapy modifies patient"s cells to combat cancer, merging immunology and genetics. It"s precise, powerful, potentially one-off treatment.
Day 1
- Arrive at the airport.
- Enjoy the provided transfer to the clinic.
- Meet your language assistant if needed.
Day 2 - Day 3
- Undergo medical examination by a specialist.
- Receive a consultation with a hematologist.
- Undertake necessary tests (blood test, biopsy).
- If required, pre-operative procedures will be performed.
Day 4
- Start the CAR T-cell therapy process.
- Your T-cells will be collected and modified.
- This process lasts for about 2-3 hours.
- Local anesthesia is typically used.
Day 5 - Day 12
- Your modified T-cells are grown in the lab.
- No direct actions are required from you.
Day 13
- Receive your modified T-cells back via infusion.
- The infusion process lasts for about 1 hour.
Day 14 - Day 20
- Stay in the clinic for observation.
- Monitor your response to the therapy.
Week 3 - Week 4
- Continue to monitor your health condition.
- Consult with medical professionals regularly.
Week 5 onwards
- Rehabilitation begins.
- Resume work and moderate activities after 6 weeks.
- Return to intense activities like sports after 8 weeks.
- Expect to see the final result after 3 months.
Please note that each case is individual. This timeline may vary based on your personal health condition and the specifics of your treatment plan.
- Bookimed deposit: $200 or €200.
- Clinic deposit: Pay a set percentage in advance.
Our Trusted Doctors
View all Doctors
Luan Tianyan
Dr. Luan Tianyan, MD, is Head of Oncology. He was recruited to Hainan Province as a high-level talent. He is a visiting scholar at the Dana-Farber Cancer Institute (USA). He is also Director of the Clinical Research Office at Bozheng Hengda International Hospital. He serves on the standing committees of the Clinical Research Management Committee (Southern Oncology Clinical Research Association), the Immunotherapy Committee (Hainan Provincial Anti-Cancer Association), and the Hainan Province Drug Research Committee.
He has more than 20 years of oncology practice. He provides individualized, comprehensive care for gastrointestinal tumors, lung cancer, and breast cancer. He focuses on pain management, palliative care, and psychological support in advanced cancer. He also works on the clinical use and study of tumor immunotherapy, including personalized mRNA vaccines and CAR-T therapy. He develops and applies proprietary drugs and related technologies.

Chen Binglai
Dr. Chen Binglai is a biological immunology expert (MD). He holds a PhD in Medicine from Central South University, with a focus on genetics and integrated TCM and Western medicine. He completed postdoctoral training at New York University and the University of Bologna. He is a visiting professor at Zhongshan Hospital, Fudan University.
He is affiliated with the Shanghai Pujiang Talent Program and the Yangpu District 3310 Talent Program. He leads the innovation project “Cancer Treatment Based on Cell Culture Technology,” supported by the Pujiang Program.
He has years of oncology practice and extensive experience in treating malignant tumors. His work focuses on the clinical use and research of CAR-T, NK cell, and stem cell therapies. He uses the Lecheng pilot program to advance clinical translation in China and to offer personalized treatment plans.

Li Ping
Dr. Li Ping, M.D., Ph.D., is Chief Physician and Professor in the Department of Hematology at Shanghai Tongji Hospital, Tongji University School of Medicine. She supervises doctoral and master's students and is an expert in hematologic malignancies.
She earned a Doctor of Medical Science from Nagoya University and completed postdoctoral research. She specializes in diagnosing and treating blood cancers. Her focus includes lymphoid malignancies—leukemias, lymphomas, and multiple myeloma. She treats patients with chemotherapy, hematopoietic stem cell transplantation, targeted therapy, and immunotherapy.
She is a pioneer in China in full-cycle CAR-T therapy for relapsed or refractory blood cancers. She leads and participates in national and international clinical trials. She serves on committees of professional societies, including the China Anti-Cancer Association. She also publishes and trains hematologists.

Xiao Yueyong
Professor Xiao Yueyong is Chief Physician in the Department of Radiological Diagnosis at the Chinese PLA General Hospital. He is a leading expert in minimally invasive interventional oncology. He serves as the inaugural President of WATA (2025–). He is President of the International (2020–) and Asian (2012–) Societies of Cryotherapy. He is also Deputy Head of the NHC Expert Group on tumour ablation regulations (2009–).
He has performed over 100,000 CT/MRI‑guided minimally invasive procedures. His work covers chemical ablation, RFA, MWA, cryoablation, and NanoKnife (IRE). He introduced and advanced NanoKnife ablation in China. He led the first national standards for tumour cryoablation and NanoKnife.
Honors include the National Special Contribution Award (Lifetime Honorary). He received First Prize from the Chinese Medicine Education Association (2021). He received two Second Prizes for Military Medical Achievements (2016, 2018) and two Second Prizes from the China Anti‑Cancer Association (2019, 2022). He was named Asian Ablation Master. His research record includes 13 Chinese patents. He is the principal investigator for four NSFC projects and one MOST subject. He has published over 200 papers, with over 110 as first or corresponding author and over 40 in SCI journals. He has led over 10 ablation guidelines or consensus statements.
Reviews about Bookimed: Discover Patients' Insights
All reviewsRelated Articles

CAR T-Cell Therapy Cost Effectiveness
Written by Anna Leonova
Share this content
Video Stories from Bookimed Patients
Anna Leonova
FAQ about CAR T-cell therapy in China
What are the clinical success rates of CAR T-cell therapy in Chinese hospitals?
Chinese hospitals report competitive CAR T-cell therapy success rates, with overall response rates between 79% and 98% for blood cancers. Specialized centers in Beijing and Guangzhou lead in treating relapsed malignancies, often achieving remission rates exceeding 90% for pediatric leukemia and nearly 99% for multiple myeloma.
- Blood cancer success: Overall response rates for B-cell malignancies typically range from 79% to 89%.
- Multiple myeloma outcomes: Domestically developed BCMA-targeted therapies show complete remission rates reaching 88.4%.
- Pediatric leukemia rates: Specialized wards report remission rates over 90% for relapsed B-cell acute lymphoblastic leukemia.
- Solid tumor progress: Emerging trials for gastrointestinal cancers show a 73% disease control rate using CT041.
Bookimed Expert Insight: China’s FasTCAR technology significantly impacts success by slashing cell manufacturing time to 24–36 hours. This rapidly prevents T-cell exhaustion, which is a common failure point in Western protocols. Clinics like Beijing GoBroad Boren Hospital leverage this speed to treat high-risk patients who cannot wait weeks for infusions.
Patient Consensus: Patients often see impressive immediate remission but emphasize that these figures reflect initial response rather than a guaranteed cure. Maintaining close proximity to intensive care units during the first 2 weeks is vital for managing safe recovery.
Which CAR T-cell products are commercially approved in China?
China has commercially approved 6 CAR T-cell therapy products for treating hematological malignancies. These therapies target CD19 or BCMA proteins to treat relapsed or refractory lymphoma, leukemia, and multiple myeloma. The National Medical Products Administration (NMPA) regulates these approvals for adult and pediatric populations.
- CD19-targeted products: Yescarta (Axi-cel), Carteyva (Relma-cel), and Yorwida (Inaticabtagene autoleucel) treat B-cell lymphomas.
- Multiple myeloma therapies: Fucaso (Equ-cel), Zevor-cel, and Carvykti (Cilta-cel) target BCMA for refractory cases.
- Approval milestones: Yescarta was the first commercial approval in 2021, followed by domestically developed Carteyva.
- Recent additions: Zevor-cel and Carvykti received NMPA approval in 2024 for advanced multiple myeloma.
Bookimed Expert Insight: While commercial approvals suggest broad availability, clinic data shows treatment accessibility is highly concentrated. Facilities like Lu Daopei Hematology Hospital manage massive volumes—200,000 patients annually—because they possess the infrastructure to handle specific commercial products. Patients should note that a 30-day hospitalization is often standard in Chinese protocols to monitor for cytokine release syndrome.
Patient Consensus: Patients often find that commercial availability in China moved faster than in Western countries. However, they emphasize verifying the brand and indication directly with major cancer centers before traveling.
Is China developing CAR T-cell therapies for solid tumors?
China is actively leading the global development of CAR T-cell therapies for solid tumors. While Western nations focus on blood cancers, Chinese biotech firms and oncology centers have scaled hundreds of clinical trials targeting gastric, pancreatic, and liver malignancies using breakthroughs like Satri-cel and Claudin18.2 targeting.
- Targeted breakthroughs: Satri-cel (CT041) is the first regulatory NDA submission for solid tumor CAR-T.
- Specific biomarkers: Trials concentrate on Glypican-3 (GPC3) and Claudin18.2 prevalent in gastrointestinal cancers.
- Agile regulations: Dual-track Investigator-Initiated Trial (IIT) frameworks fast-track therapies to late-stage patients.
- Advanced manufacturing: Closed-loop automation platforms reduce cell production timelines to 24–36 hours.
Bookimed Expert Insight: While large centers like Lu Daopei Hematology Hospital manage 200,000 patients annually, solid tumor CAR-T remains largely investigational. You should prioritize clinics like JCI-accredited Fuda Cancer Hospital. They often combine cellular therapies with minimally invasive techniques like NanoKnife to help penetrate dense tumor masses.
Patient Consensus: Patients value the speed of Chinese innovation but warn that many breakthroughs are small-scale trials. You must verify if a therapy is in an active clinical trial phase.
How long does the CAR T-cell treatment process take in China?
The CAR T-cell treatment process in China typically takes 4 to 8 weeks for the clinical phases. International patients should plan for 1 to 3 months to include pre-assessments and final follow-ups within JCI-accredited facilities like Lu Daopei Hematology Hospital or Fuda Cancer Hospital.
- Pre-treatment assessment: Medical evaluations and tumor typing take 1 to 2 weeks for eligibility.
- Cell manufacturing: Advanced proprietary platforms like FasTCAR reduce engineering time to 24–36 hours.
- Conditioning phase: A 3-day chemotherapy regimen prepares the body for successful cell infusion.
- Inpatient monitoring: Patients stay in specialized wards for 14 to 30 days post-infusion.
Bookimed Expert Insight: While standard manufacturing takes weeks, China's massive hematology centers like Lu Daopei Hospital manage 200,000 patients annually. This high volume allows clinics to offer specialized packages, like those at Beijing GoBroad Boren Hospital, which include 30 full days of hospitalization. This extended stay ensures immediate management of potential side effects like CRS or neurotoxicity during the most critical recovery window.
Patient Consensus: Patients report that while cell collection is quick, manufacturing waits and post-infusion monitoring are the longest phases. Having a bridging therapy plan ready is vital if the disease progresses during the production stage.









